The patent is based on Peptonic's clinically proven gel base which has been adapted to target candida albicans, the most common cause of vaginal yeast infections. The gel is designed to moisturize and balance the natural pH in the intimate area, while gently preserving the delicate vaginal flora. A clinical study on a limited population of women showed a good effect against Candida albicans, highlighting its potential to treat and prevent vaginal yeast infections.

"The granted patent not only protects our unique formulation in treating yeast infections but also constitutes a fundamental part of our ambition to enabling women to independently self-diagnose, treat, and prevent common medical conditions in the intimate area," says Anna Linton, CEO of Peptonic.

Vaginal yeast infections are a prevalent condition affecting up to three out of four women at some point in their lives, with many experiencing recurring infections. Globally, there are indications of and concerns about resistance development to available treatments, creating a need for new treatment options.

For more information contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone:  +46 70-244 92 07

About Peptonic Medical AB                                                                                                      
Peptonic Medical AB (publ) is an innovative Swedish biomedical company engaged in the development and sales of clinically proven self-care treatments and self-diagnostic rapid tests in intimate women's health. The portfolio is sold under the brands Vagivital and Vernivia.

Peptonic Medical is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and rapid self-diagnostic tests in intimate women's health. Under the esteemed brands Vagivital and Vernivia, the portfolio delivers tangible solutions. The company's vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively.

The company continuously aims to broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners.

The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense in the USA and Peptonic Medical in Israel. Peptonic Medical was founded in 2009, and the company's shares have been listed on the Spotlight Stock Market since 2014.